Celldex Therapeutics (NASDAQ:CLDX) Receives New Coverage from Analysts at TD Cowen

TD Cowen started coverage on shares of Celldex Therapeutics (NASDAQ:CLDX – Free Report) in a research note issued to investors on Wednesday morning, Marketbeat reports. The firm issued an outperform rating on the biopharmaceutical company’s stock. Several other analysts have also recently weighed in on CLDX. HC Wainwright raised their price objective on shares of […]

Leave a Reply

Your email address will not be published.

Previous post TowneBank (NASDAQ:TOWN) Rating Increased to Hold at StockNews.com
Next post DocuSign (NASDAQ:DOCU) Downgraded by Wells Fargo & Company